We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biovail Gains US Rights to Wellbutrin XL Brand, Takes on Rivals
Biovail Gains US Rights to Wellbutrin XL Brand, Takes on Rivals
May 6, 2009
GlaxoSmithKline (GSK) is selling its U.S. rights for the antidepressant Wellbutrin XL to its partner Biovail for $510 million.